https://news.medxy.ai/long-term-outcomes-of-dysphagia-following-type-i-laryngeal-cleft-repair-in-children/Medxy AIen2026-09-29T10:41:38-07:00Long-Term Outcomes of Dysphagia Following Type I Laryngeal Cleft Repair in Children https://news.medxy.ai/zh/thyroid-surgery-parathyroid-injury/Medxy AIzh2026-09-29T10:41:04-07:00甲状腺手术中误切甲状旁腺：发生率、危险因素与临床影响 https://news.medxy.ai/ja/accidental-parathyroidectomy/Medxy AIja2026-09-29T10:40:47-07:00甲状腺手術中の偶発的副甲状腺切除：発生率・リスク因子・臨床的意義 https://news.medxy.ai/vi/79083-2/Medxy AIvi2026-09-29T10:40:27-07:00Cắt bỏ tuyến cận giáp ngoài ý muốn trong phẫu thuật tuyến giáp: Tỷ lệ mắc, yếu tố nguy cơ và ý nghĩa lâm sàng https://news.medxy.ai/inadvertent-parathyroidectomy-during-thyroid-surgery-incidence-risk-factors-and-clinical-implications/Medxy AIen2026-09-29T10:40:07-07:00Inadvertent Parathyroidectomy During Thyroid Surgery: Incidence, Risk Factors, and Clinical Implications https://news.medxy.ai/zh/surgery-teacher-retention/Medxy AIzh2026-09-29T10:39:26-07:00外科教师为何留任或离职：影响去留决策的关键因素 https://news.medxy.ai/ja/79073-2/Medxy AIja2026-09-29T10:39:09-07:00外科系教員の引き留め：残留か離職かを左右する重要な要因 https://news.medxy.ai/vi/retain-surgery-instructors/Medxy AIvi2026-09-29T10:38:50-07:00Giữ chân giảng viên phẫu thuật: Những yếu tố then chốt quyết định ở lại hay rời đi https://news.medxy.ai/understanding-surgical-faculty-retention-key-factors-influencing-their-decision-to-stay-or-leave/Medxy AIen2026-09-29T10:38:33-07:00Understanding Surgical Faculty Retention: Key Factors Influencing Their Decision to Stay or Leave https://news.medxy.ai/zh/79065-2/Medxy AIzh2026-09-29T10:37:53-07:00多发性硬化症中多领域生活方式干预的持续效应——基于LIMS研究24个月随访的启示 https://news.medxy.ai/ja/multiple-sclerosis-lifestyle/Medxy AIja2026-09-29T10:37:35-07:00多発性硬化症における多領域ライフスタイル介入の持続効果――LIMS研究24か月追跡から見えた示唆 https://news.medxy.ai/vi/sustainable-lifestyle-benefits/Medxy AIvi2026-09-29T10:37:12-07:00Lợi ích bền vững của can thiệp lối sống đa mô thức ở bệnh đa xơ cứng: Những phát hiện từ theo dõi 24 tháng của nghiên cứu LIMS https://news.medxy.ai/sustained-benefits-of-a-multidomain-lifestyle-intervention-in-multiple-sclerosis-insights-from-the-24-month-lims-study-follow-up/Medxy AIen2026-09-29T10:36:51-07:00Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis: Insights from the 24-Month LIMS Study Follow-Up https://news.medxy.ai/zh/gastric-emptying-glp1/Medxy AIzh2026-09-29T10:36:02-07:00术后减重手术低血糖中的胃排空加速：GLP-1受体激动剂的作用再评估 https://news.medxy.ai/ja/postoperative-hypoglycemia/Medxy AIja2026-09-29T10:35:47-07:00術後低血糖における胃排出亢進：GLP-1受容体作動薬の位置づけを検討する https://news.medxy.ai/vi/empty-stomach-after-bariatric-surgery/Medxy AIvi2026-09-29T10:35:25-07:00Làm rỗng dạ dày nhanh trong hạ đường huyết sau phẫu thuật béo phì: Đánh giá vai trò của chất chủ vận thụ thể GLP-1 https://news.medxy.ai/rapid-gastric-emptying-in-postbariatric-hypoglycemia-evaluating-the-role-of-glp-1-receptor-agonists/Medxy AIen2026-09-29T10:35:07-07:00Rapid Gastric Emptying in Postbariatric Hypoglycemia: Evaluating the Role of GLP-1 Receptor Agonists https://news.medxy.ai/zh/semaglutide-weight-loss-4/Medxy AIzh2026-09-29T10:34:16-07:00司美格鲁肽在心血管患者中的最大减重预测因素：SELECT试验带来的启示 https://news.medxy.ai/ja/semaglutide-weight-loss-3/Medxy AIja2026-09-29T10:33:58-07:00SELECT試験が示した、心血管疾患患者におけるセマグルチド減量効果の予測因子とは https://news.medxy.ai/vi/weight-loss-predictors-semaglutide/Medxy AIvi2026-09-29T10:33:40-07:00Những yếu tố nào dự báo mức giảm cân tối đa với semaglutide ở bệnh nhân tim mạch? Góc nhìn từ thử nghiệm SELECT https://news.medxy.ai/unraveling-the-predictors-of-peak-weight-loss-with-semaglutide-in-cardiovascular-patients-insights-from-the-select-trial/Medxy AIen2026-09-29T10:33:23-07:00Unraveling the Predictors of Peak Weight Loss with Semaglutide in Cardiovascular Patients: Insights from the SELECT Trial https://news.medxy.ai/zh/hodgkin-lymphoma-immunotherapy/Medxy AIzh2026-09-29T10:30:01-07:00经典霍奇金淋巴瘤中免疫检查点抑制剂再挑战：来自院外队列的疗效与安全性启示 https://news.medxy.ai/ja/hodgkin-lymphoma-immunotherapy-2/Medxy AIja2026-09-29T10:29:44-07:00古典的ホジキンリンパ腫における免疫チェックポイント阻害薬再投与：治験外コホートからみた有効性と安全性 https://news.medxy.ai/vi/immune-checkpoint-inhibitors-2/Medxy AIvi2026-09-29T10:29:24-07:00Tái dùng thuốc ức chế điểm kiểm soát miễn dịch trong u lympho Hodgkin kinh điển: Những góc nhìn về hiệu quả và độ an toàn từ một đoàn hệ ngoài thử nghiệm https://news.medxy.ai/immune-checkpoint-inhibitor-rechallenge-in-classical-hodgkin-lymphoma-efficacy-and-safety-insights-from-an-off-trial-cohort/Medxy AIen2026-09-29T10:29:07-07:00Immune Checkpoint Inhibitor Rechallenge in Classical Hodgkin Lymphoma: Efficacy and Safety Insights from an Off-Trial Cohort https://news.medxy.ai/zh/79034-2/Medxy AIzh2026-09-29T10:28:28-07:00靶向 TYK2：CALR 突变型骨髓增殖性肿瘤的一个新型治疗靶点 https://news.medxy.ai/ja/calr-mutant-mpns-therapy/Medxy AIja2026-09-29T10:28:08-07:00CALR変異陽性MPNsにおける新たな治療脆弱性：TYK2を標的とする戦略 https://news.medxy.ai/vi/tyk2-target-mutation/Medxy AIvi2026-09-29T10:27:41-07:00Nhắm trúng TYK2: điểm yếu điều trị mới trong u tân sinh tăng sinh tủy mang đột biến CALR https://news.medxy.ai/targeting-tyk2-a-novel-therapeutic-vulnerability-in-calr-mutant-myeloproliferative-neoplasms/Medxy AIen2026-09-29T10:27:19-07:00Targeting TYK2: A Novel Therapeutic Vulnerability in CALR-Mutant Myeloproliferative Neoplasms https://news.medxy.ai/zh/fibroblasts-pitavastatin-treatment/Medxy AIzh2026-09-29T10:26:34-07:00纤维细胞与 pitavastatin 在 JAK2V617F 突变型骨髓纤维化中的治疗潜力：一项综合综述 https://news.medxy.ai/ja/jak2v617f-myelofibrosis-treatment/Medxy AIja2026-09-29T10:26:15-07:00JAK2V617F変異骨髄線維症における線維細胞とpitavastatinの治療可能性：包括的レビュー https://news.medxy.ai/vi/fibrocytes-pitavastatin-myelofibrosis/Medxy AIvi2026-09-29T10:25:53-07:00Fibrocytes và tiềm năng điều trị của pitavastatin trong myelofibrosis đột biến JAK2V617F: Tổng quan toàn diện https://news.medxy.ai/fibrocytes-and-therapeutic-potential-of-pitavastatin-in-jak2v617f-mutated-myelofibrosis-a-comprehensive-review/Medxy AIen2026-09-29T10:25:31-07:00Fibrocytes and Therapeutic Potential of Pitavastatin in JAK2V617F-Mutated Myelofibrosis: A Comprehensive Review https://news.medxy.ai/zh/pulmonary-artery-dilation/Medxy AIzh2026-09-29T10:24:34-07:00慢性肺疾病中肺动脉扩张：肺动脉高压的影像学信号——来自PVDOMICS队列的研究 https://news.medxy.ai/ja/pulmonary-hypertension-markers/Medxy AIja2026-09-29T10:24:17-07:00慢性肺疾患における肺高血圧の指標としての肺動脈拡張：PVDOMICSコホートからの知見 https://news.medxy.ai/vi/pulmonary-artery-dilation-2/Medxy AIvi2026-09-29T10:23:58-07:00Giãn động mạch phổi trên CT ngực: Dấu ấn gợi ý tăng áp phổi trong bệnh phổi mạn tính từ đoàn hệ PVDOMICS https://news.medxy.ai/pulmonary-artery-dilation-as-a-mark-of-pulmonary-hypertension-in-chronic-lung-disease-insights-from-the-pvdomics-cohort/Medxy AIen2026-09-29T10:23:41-07:00Pulmonary Artery Dilation as a Mark of Pulmonary Hypertension in Chronic Lung Disease: Insights from the PVDOMICS Cohort https://news.medxy.ai/zh/copd-progression-prediction/Medxy AIzh2026-09-29T10:22:51-07:00通过1年CT肺气肿亚型进展预测COPD肺功能下降：SPIROMICS研究新启示 https://news.medxy.ai/ja/copd-progress-prediction/Medxy AIja2026-09-29T10:22:34-07:001年間のCT肺気腫サブタイプ進展からみるCOPDの肺機能低下予測：SPIROMICS研究の示唆 https://news.medxy.ai/vi/copd-lung-function-decline/Medxy AIvi2026-09-29T10:22:13-07:00Dự báo suy giảm chức năng phổi ở COPD qua tiến triển 1 năm của phân nhóm khí phế thũng trên CT: Những phát hiện từ SPIROMICS https://news.medxy.ai/predicting-lung-function-decline-in-copd-via-one-year-ct-emphysema-subtype-progression-insights-from-spiromics/Medxy AIen2026-09-29T10:21:52-07:00Predicting Lung Function Decline in COPD via One-Year CT Emphysema Subtype Progression: Insights from SPIROMICS https://news.medxy.ai/zh/eyelid-drooping-assessment/Medxy AIzh2026-09-29T10:21:07-07:00眼睑下垂评估迈入新阶段：基于智能手机的3D眼部重建提升精确度与临床决策能力 https://news.medxy.ai/ja/eyelid-ptosis-evaluation/Medxy AIja2026-09-29T10:20:48-07:00眼瞼下垂評価を次の段階へ：スマートフォン3D眼再構成が精度と臨床判断を高める https://news.medxy.ai/vi/eyelid-droop-3d-reconstruction/Medxy AIvi2026-09-29T10:20:28-07:00Đánh Giá Sụp Mi Tiến Bộ Hơn: Tái Tạo Nhãn Cầu 3D Bằng Điện Thoại Thông Minh Nâng Cao Độ Chính Xác và Quyết Định Lâm Sàng https://news.medxy.ai/advancing-blepharoptosis-assessment-smartphone-based-3d-ocular-reconstruction-enhances-precision-and-clinical-decision-making/Medxy AIen2026-09-29T10:20:09-07:00Advancing Blepharoptosis Assessment: Smartphone-Based 3D Ocular Reconstruction Enhances Precision and Clinical Decision-Making https://news.medxy.ai/zh/cambridge-freezing-therapy-2/Medxy AIzh2026-09-29T10:19:27-07:00Cambridge预防性冷冻治疗：降低2型Stickler综合征视网膜脱离风险的有效策略 https://news.medxy.ai/ja/cambridge-freezing-therapy/Medxy AIja2026-09-29T10:19:11-07:00Cambridge予防的凍結療法で2型スティックラー症候群の網膜剥離を強力に予防 https://news.medxy.ai/vi/cold-therapy-stickler-type-2/Medxy AIvi2026-09-29T10:18:52-07:00Liệu pháp lạnh dự phòng Cambridge: giải pháp hiệu quả ngăn bong võng mạc ở hội chứng Stickler type 2 https://news.medxy.ai/effective-retinal-detachment-prevention-in-type-2-stickler-syndrome-using-cambridge-prophylactic-cryotherapy/Medxy AIen2026-09-29T10:18:33-07:00Effective Retinal Detachment Prevention in Type 2 Stickler Syndrome Using Cambridge Prophylactic Cryotherapy https://news.medxy.ai/zh/low-awakening-threshold-predicts-compliance/Medxy AIzh2026-09-29T10:17:55-07:00低觉醒阈值可预测阻塞性睡眠呼吸暂停患者对舌下神经刺激的长期依从性 https://news.medxy.ai/ja/low-arousal-threshold/Medxy AIja2026-09-29T10:17:38-07:00低覚醒閾値は舌下神経刺激療法の長期継続を予測できるか https://news.medxy.ai/vi/low-arousal-threshold-2/Medxy AIvi2026-09-29T10:17:16-07:00Ngưỡng thức giấc thấp: Dấu hiệu dự báo tuân thủ lâu dài với kích thích thần kinh hạ thiệt trong ngưng thở tắc nghẽn khi ngủ https://news.medxy.ai/low-arousal-threshold-as-a-predictor-of-long-term-adherence-to-hypoglossal-nerve-stimulation-in-obstructive-sleep-apnea/Medxy AIen2026-09-29T10:16:57-07:00Low Arousal Threshold as a Predictor of Long-Term Adherence to Hypoglossal Nerve Stimulation in Obstructive Sleep Apnea https://news.medxy.ai/zh/hearing-loss-outcomes/Medxy AIzh2026-09-29T10:16:12-07:00耳聋越久，效果越差吗？——人工耳蜗植入后言语结局的十年临床数据揭秘 https://news.medxy.ai/ja/hearing-implant-benefits/Medxy AIja2026-09-29T10:15:56-07:00難聴期間が長くても人工内耳で改善は得られるのか：10年にわたる臨床データからの知見 https://news.medxy.ai/vi/hearing-loss-outcomes-2/Medxy AIvi2026-09-29T10:15:37-07:00Điếc kéo dài và kết quả lời nói sau cấy ốc tai điện tử: Góc nhìn từ dữ liệu lâm sàng 10 năm https://news.medxy.ai/prolonged-deafness-duration-and-speech-outcomes-after-cochlear-implantation-insights-from-a-decade-of-clinical-data/Medxy AIen2026-09-29T10:15:17-07:00Prolonged Deafness Duration and Speech Outcomes After Cochlear Implantation: Insights from a Decade of Clinical Data https://news.medxy.ai/zh/necrotizing-pancreatitis-colon-fistula/Medxy AIzh2026-09-29T10:14:40-07:00坏死性胰腺炎相关结肠瘘的非手术处理：识别适合保守治疗的患者 https://news.medxy.ai/ja/necrotizing-pancreatitis-colon-fistula-2/Medxy AIja2026-09-29T10:14:21-07:00壊死性膵炎に伴う結腸瘻の非手術的管理：保存的治療の適応を見極める https://news.medxy.ai/vi/78954-2/Medxy AIvi2026-09-29T10:13:59-07:00Quản lý không phẫu thuật đối với rò đại tràng liên quan đến viêm tụy hoại tử: xác định các bệnh nhân phù hợp với điều trị bảo tồn https://news.medxy.ai/nonoperative-management-of-colonic-fistulas-in-necrotizing-pancreatitis-identifying-candidates-for-conservative-care/Medxy AIen2026-09-29T10:13:41-07:00Nonoperative Management of Colonic Fistulas in Necrotizing Pancreatitis: Identifying Candidates for Conservative Care https://news.medxy.ai/ja/colon-rectal-trauma-treatment/Medxy AIja2026-09-29T10:12:58-07:00結腸・直腸外傷の治療は生理学で選ぶ時代へ：2026年WSESコンセンサスの重要推奨 https://news.medxy.ai/vi/selective-care-colorectal-trauma/Medxy AIvi2026-09-29T10:12:23-07:00Chăm sóc chọn lọc, dựa trên sinh lý trong chấn thương đại trực tràng: các khuyến cáo then chốt từ đồng thuận WSES 2026 https://news.medxy.ai/zh/colon-rectal-trauma/Medxy AIzh2026-09-29T10:11:50-07:00结肠与直肠创伤的选择性、生理驱动型处理：2026年WSES共识关键建议 https://news.medxy.ai/selective-physiology-driven-care-for-colon-and-rectal-trauma-key-recommendations-from-the-2026-wses-consensus/Medxy AIen2026-09-29T10:11:21-07:00Selective, Physiology-Driven Care for Colon and Rectal Trauma: Key Recommendations from the 2026 WSES Consensus https://news.medxy.ai/zh/her2-scoring-discrepancy/Medxy AIzh2026-09-29T10:10:18-07:00子宫内膜取样与子宫切除标本的胃癌HER2评分为何不一致：高分级子宫内膜癌的临床启示 https://news.medxy.ai/ja/78934-2/Medxy AIja2026-09-29T10:10:00-07:00子宮内膜生検検体と子宮摘出検体におけるHER2スコアの不一致：高悪性度子宮内膜癌における臨床的意義 https://news.medxy.ai/vi/her2-gastric-endometrial-cancer/Medxy AIvi2026-09-29T10:09:40-07:00Điểm HER2 theo tiêu chuẩn dạ dày ở sinh thiết nội mạc tử cung và bệnh phẩm cắt tử cung: Hệ quả lâm sàng trong ung thư nội mạc tử cung độ cao https://news.medxy.ai/discordance-between-gastric-her2-scoring-in-endometrial-sampling-versus-hysterectomy-specimens-clinical-implications-in-high-grade-endometrial-cancer/Medxy AIen2026-09-29T10:09:22-07:00Discordance Between Gastric HER2 Scoring in Endometrial Sampling Versus Hysterectomy Specimens: Clinical Implications in High-Grade Endometrial Cancer https://news.medxy.ai/zh/peritoneal-fluid-exosomes/Medxy AIzh2026-09-29T10:08:42-07:00腹膜液小细胞外囊泡蛋白：开启子宫内膜异位症诊断新潜力 https://news.medxy.ai/ja/endometriosis-diagnostics/Medxy AIja2026-09-29T10:08:23-07:00子宮内膜症における腹膜液由来小型細胞外小胞タンパク質の診断的可能性を探る https://news.medxy.ai/vi/protein-diagnostics-endometriosis/Medxy AIvi2026-09-29T10:08:02-07:00Tiềm năng chẩn đoán của protein trong túi ngoại bào kích thước nhỏ từ dịch phúc mạc ở lạc nội mạc tử cung https://news.medxy.ai/unlocking-the-diagnostic-potential-of-peritoneal-fluid-small-extracellular-vesicle-proteins-in-endometriosis/Medxy AIen2026-09-29T10:07:41-07:00Unlocking the Diagnostic Potential of Peritoneal Fluid Small Extracellular Vesicle Proteins in Endometriosis https://news.medxy.ai/ja/78912-2/Medxy AIja2026-09-29T10:07:03-07:00肝細胞癌に対する全身療法と手術・局所領域療法の併用：HCC-Live専門家コンセンサスによる臨床試験デザインへの重要な提言 https://news.medxy.ai/vi/hcc-live-guidelines/Medxy AIvi2026-09-29T10:06:27-07:00Thiết kế thử nghiệm chặt chẽ cho liệu pháp toàn thân kết hợp phẫu thuật và điều trị tại chỗ-vùng trong ung thư biểu mô tế bào gan: khuyến nghị then chốt từ đồng thuận chuyên gia HCC-Live https://news.medxy.ai/zh/hcc-treatment-guidelines/Medxy AIzh2026-09-29T10:05:55-07:00肝细胞癌系统治疗联合手术与局部区域治疗：HCC-Live专家共识对临床试验设计的关键建议 https://news.medxy.ai/designing-rigorous-trials-of-systemic-therapy-with-surgery-and-locoregional-treatment-in-hepatocellular-carcinoma-key-recommendations-from-an-hcc-live-expert-consensus/Medxy AIen2026-09-29T10:05:25-07:00Designing Rigorous Trials of Systemic Therapy with Surgery and Locoregional Treatment in Hepatocellular Carcinoma: Key Recommendations from an HCC-Live Expert Consensus https://news.medxy.ai/zh/ms-treatment-progress/Medxy AIzh2026-09-29T10:04:16-07:00进展型多发性硬化治疗评估新进展：MAMS临床试验中的患者报告中期结局 https://news.medxy.ai/ja/progressive-ms-treatment/Medxy AIja2026-09-29T10:03:56-07:00進行型多発性硬化症における治療評価の前進：MAMS臨床試験における患者報告アウトカムの中間評価 https://news.medxy.ai/vi/78898-2/Medxy AIvi2026-09-29T10:03:35-07:00Những tiến bộ mới trong đánh giá hiệu quả điều trị bệnh đa xơ cứng tiến triển: Các kết quả trung gian do bệnh nhân tự báo cáo trong các thử nghiệm lâm sàng MAMS https://news.medxy.ai/advancing-treatment-evaluation-in-progressive-multiple-sclerosis-interim-patient-reported-outcomes-for-mams-clinical-trials/Medxy AIen2026-09-29T10:03:15-07:00Advancing Treatment Evaluation in Progressive Multiple Sclerosis: Interim Patient-Reported Outcomes for MAMS Clinical Trials https://news.medxy.ai/zh/lecanemab-alzheimers-biomarkers/Medxy AIzh2026-09-29T10:02:35-07:00动态血浆生物标志物揭示 lecanemab 在早期阿尔茨海默病中的多重作用 https://news.medxy.ai/ja/78894-2/Medxy AIja2026-09-29T10:02:18-07:00動的な血漿バイオマーカーが明らかにする、早期アルツハイマー病におけるレカネマブの多面的な作用 https://news.medxy.ai/vi/lecanemab-alzheimer-impact/Medxy AIvi2026-09-29T10:01:56-07:00Dấu ấn sinh học huyết tương động cho thấy tác động đa chiều của lecanemab ở bệnh Alzheimer giai đoạn sớm https://news.medxy.ai/dynamic-plasma-biomarkers-reveal-multifaceted-effects-of-lecanemab-in-early-alzheimers-disease/Medxy AIen2026-09-29T10:01:33-07:00Dynamic Plasma Biomarkers Reveal Multifaceted Effects of Lecanemab in Early Alzheimer’s Disease https://news.medxy.ai/zh/diabetes-vessel-reconstruction/Medxy AIzh2026-09-29T10:00:52-07:00下肢动脉与冠状动脉血运重建中的糖尿病病程及晚期并发症差异：一项比较性综述 https://news.medxy.ai/ja/diabetes-complications-comparison/Medxy AIja2026-09-29T10:00:32-07:00下肢動脈疾患と冠動脈疾患における糖尿病罹病期間・高度合併症の比較：血行再建をめぐる総説 https://news.medxy.ai/vi/diabetes-complications-comparison-2/Medxy AIvi2026-09-29T10:00:09-07:00Thời gian mắc đái tháo đường và các biến chứng đái tháo đường tiến triển ở tái thông mạch chi dưới so với tái thông mạch vành: Tổng quan so sánh https://news.medxy.ai/diabetes-duration-and-advanced-diabetes-related-complications-in-lower-extremity-versus-coronary-revascularization-a-comparative-review/Medxy AIen2026-09-29T09:59:47-07:00Diabetes Duration and Advanced Diabetes-Related Complications in Lower-Extremity Versus Coronary Revascularization: A Comparative Review https://news.medxy.ai/zh/automated-insulin-delivery-5/Medxy AIzh2026-09-29T09:58:53-07:00弥合空白：推进1型糖尿病孕妇的自动化胰岛素输注技术发展 https://news.medxy.ai/ja/automated-insulin-pregnancy/Medxy AIja2026-09-29T09:58:34-07:00妊娠中の1型糖尿病に対する自動インスリン投与の進化：医療の空白を埋める https://news.medxy.ai/vi/insulin-automation-pregnancy/Medxy AIvi2026-09-29T09:58:13-07:00Thu hẹp khoảng cách: thúc đẩy tự động đưa insulin cho phụ nữ mang thai mắc đái tháo đường type 1 https://news.medxy.ai/bridging-the-gap-advancing-automated-insulin-delivery-for-pregnant-women-with-type-1-diabetes/Medxy AIen2026-09-29T09:57:52-07:00Bridging the Gap: Advancing Automated Insulin Delivery for Pregnant Women with Type 1 Diabetes https://news.medxy.ai/zh/precision-therapy-lqt2/Medxy AIzh2026-09-28T09:57:09-07:00精准治疗长 QT 综合征2型：Lumacaftor纠正转运缺陷并缩短QT间期 https://news.medxy.ai/ja/78879-2/Medxy AIja2026-09-28T09:56:51-07:00ルマカフトール、2型QT延長症候群の精密治療薬として期待 https://news.medxy.ai/vi/precision-medicine-qt-syndrome/Medxy AIvi2026-09-28T09:56:27-07:00Y học chính xác cho hội chứng QT dài тип 2: Lumacaftor khắc phục khiếm khuyết vận chuyển và rút ngắn khoảng QT https://news.medxy.ai/precision-medicine-for-long-qt-syndrome-type-2-lumacaftor-corrects-trafficking-defects-and-shortens-qt-interval/Medxy AIen2026-09-28T09:56:08-07:00Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval https://news.medxy.ai/zh/cancer-gender-differences/Medxy AIzh2026-09-28T09:55:34-07:00癌症发病的性别差异：生活方式与健康因素的综合证据 https://news.medxy.ai/vi/venetoclax-inotuzumab-results/Medxy AIvi2026-09-28T09:55:14-07:00Phối hợp Venetoclax và Inotuzumab Ozogamicin cho thấy kết quả đầy hứa hẹn trong bệnh bạch cầu lympho cấp dòng B tái phát/kháng trị https://news.medxy.ai/vi/gender-cancer-differences/Medxy AIvi2026-09-28T09:54:45-07:00Khác biệt theo giới trong tỷ lệ mắc ung thư: vai trò của lối sống và các tình trạng sức khỏe liên quan https://news.medxy.ai/disparities-in-cancer-incidence-by-sex-and-associated-lifestyle-factors-and-health-conditions-an-integrative-review/Medxy AIen2026-09-28T09:54:22-07:00Disparities in Cancer Incidence by Sex and Associated Lifestyle Factors and Health Conditions: An Integrative Review https://news.medxy.ai/zh/semaglutide-cardiovascular-benefits/Medxy AIzh2026-09-28T08:51:30-07:00司美格鲁肽心血管获益机制再审视：SELECT 试验中介分析解读 https://news.medxy.ai/ja/semaglutide-cardiovascular-protection/Medxy AIja2026-09-28T08:51:13-07:00セマグルチドの心血管保護作用を読み解く：SELECT試験の媒介分析から見えた示唆 https://news.medxy.ai/zh/leukemia-immunotherapy/Medxy AIzh2026-09-28T06:05:15-07:00超越传统靶点：急性髓系白血病精准免疫治疗的新进展 https://news.medxy.ai/ja/precision-immunotherapy/Medxy AIja2026-09-28T06:04:56-07:00急性骨髄性白血病における精密免疫療法：従来標的を超えて https://news.medxy.ai/vi/precision-immunotherapy-in-leukemia/Medxy AIvi2026-09-28T06:04:36-07:00Liệu pháp miễn dịch chính xác trong bạch cầu cấp dòng tủy: Vượt ra ngoài các mục tiêu truyền thống https://news.medxy.ai/precision-immunotherapy-in-acute-myeloid-leukemia-advancing-beyond-traditional-targets/Medxy AIen2026-09-28T06:04:15-07:00Precision Immunotherapy in Acute Myeloid Leukemia: Advancing Beyond Traditional Targets https://news.medxy.ai/zh/mertk-cll-strategy-2/Medxy AIzh2026-09-28T06:03:34-07:00靶向CLL中的MERTK：克服ibrutinib耐药的潜在新策略 https://news.medxy.ai/ja/mertk-targeting-cll/Medxy AIja2026-09-28T06:03:17-07:00CLLにおけるMERTK標的化：Ibrutinib耐性を克服する有望な戦略 https://news.medxy.ai/vi/mertk-cll-strategy/Medxy AIvi2026-09-28T06:02:58-07:00Nhắm đích MERTK trong CLL: Chiến lược đầy hứa hẹn để vượt qua tình trạng kháng ibrutinib https://news.medxy.ai/targeting-mertk-in-cll-a-promising-strategy-for-overcoming-ibrutinib-resistance/Medxy AIen2026-09-28T06:02:37-07:00Targeting MERTK in CLL: A Promising Strategy for Overcoming Ibrutinib Resistance https://news.medxy.ai/zh/adamts13-treatment-benefits/Medxy AIzh2026-09-28T06:02:00-07:00重组ADAMTS13治疗在先天性血栓性血小板减少性紫癜中疗效与安全性优于血浆治疗：3期试验最终结果 https://news.medxy.ai/ja/adamts13-therapy-results/Medxy AIja2026-09-28T06:01:41-07:00先天性TTPに対する組換えADAMTS13療法、血漿療法を上回る有効性と安全性を示す：第3相試験最終結果 https://news.medxy.ai/vi/adamts13-recombinant-benefits/Medxy AIvi2026-09-28T06:01:20-07:00ADAMTS13 tái tổ hợp cho thấy hiệu quả và độ an toàn vượt trội so với liệu pháp huyết tương trong TTP bẩm sinh: Kết quả cuối cùng của thử nghiệm pha 3 https://news.medxy.ai/recombinant-adamts13-therapy-demonstrates-superior-efficacy-and-safety-over-plasma-based-therapy-in-congenital-thrombotic-thrombocytopenic-purpura-final-phase-3-trial-results/Medxy AIen2026-09-28T06:01:01-07:00Recombinant ADAMTS13 Therapy Demonstrates Superior Efficacy and Safety Over Plasma-Based Therapy in Congenital Thrombotic Thrombocytopenic Purpura: Final Phase 3 Trial Results https://news.medxy.ai/zh/srage-ards-lung-recruitment/Medxy AIzh2026-09-28T06:00:24-07:00血浆sRAGE生物标志物助力ARDS个体化肺复张：基于LIVE试验的研究解读 https://news.medxy.ai/ja/plasma-srage-ards/Medxy AIja2026-09-28T06:00:04-07:00血漿sRAGEバイオマーカーがARDSの個別化肺リクルートメント戦略を導く：LIVE試験からの知見 https://news.medxy.ai/vi/srage-plasma-ards/Medxy AIvi2026-09-28T05:59:43-07:00sRAGE huyết tương: chỉ dấu định hướng chiến lược tuyển mộ phổi cá thể hóa trong ARDS từ thử nghiệm LIVE https://news.medxy.ai/plasma-srage-biomarker-guides-personalized-lung-recruitment-strategies-in-ards-insights-from-the-live-trial/Medxy AIen2026-09-28T05:59:22-07:00Plasma sRAGE Biomarker Guides Personalized Lung Recruitment Strategies in ARDS: Insights from the LIVE Trial https://news.medxy.ai/zh/inhaled-treprostinil-ipf-2/Medxy AIzh2026-09-28T05:58:46-07:00吸入性 Treprostinil 在特发性肺纤维化中的应用：TETON-1 与 TETON-2 Ⅲ期联合试验的有力证据 https://news.medxy.ai/ja/treprostinil-ipf-trials/Medxy AIja2026-09-28T05:58:30-07:00特発性肺線維症に対する吸入用Treprostinil：TETON-1・TETON-2第3相試験統合解析が示す確かなエビデンス https://news.medxy.ai/vi/inhaled-treprostinil-ipf/Medxy AIvi2026-09-28T05:58:13-07:00Treprostinil dạng hít trong xơ phổi vô căn: Bằng chứng vững chắc từ phân tích gộp hai thử nghiệm giai đoạn 3 TETON-1 và TETON-2 https://news.medxy.ai/inhaled-treprostinil-in-idiopathic-pulmonary-fibrosis-robust-evidence-from-the-combined-teton-1-and-teton-2-phase-3-trials/Medxy AIen2026-09-28T05:57:56-07:00Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Robust Evidence from the Combined TETON-1 and TETON-2 Phase 3 Trials https://news.medxy.ai/zh/hess-screen-test/Medxy AIzh2026-09-28T05:57:15-07:00Hess屏幕试验：区分去代偿性内隐斜与眼睑下垂综合征的关键工具 https://news.medxy.ai/ja/esophoria-eye-syndrome/Medxy AIja2026-09-28T05:57:00-07:00Hess Screen Testで見抜く：decompensated esophoriaとsagging eye syndromeの鑑別 https://news.medxy.ai/vi/hess-screen-test-2/Medxy AIvi2026-09-28T05:56:42-07:00Hess Screen Test: Công cụ then chốt để phân biệt lé ẩn trong trạng thái mất bù với hội chứng mắt sa trễ https://news.medxy.ai/hess-screen-test-a-crucial-tool-to-differentiate-decompensated-esophoria-from-sagging-eye-syndrome/Medxy AIen2026-09-28T05:56:22-07:00Hess Screen Test: A Crucial Tool to Differentiate Decompensated Esophoria from Sagging Eye Syndrome https://news.medxy.ai/ja/botulinum-toxin-throat/Medxy AIja2026-09-28T05:55:46-07:00声門上ボツリヌス毒素注射が喉頭感覚障害の症状を改善 https://news.medxy.ai/vi/botulinum-toxin-treatment/Medxy AIvi2026-09-28T05:55:29-07:00Tiêm Botulinum Toxin vùng trên thanh môn giúp cải thiện triệu chứng rối loạn cảm giác thanh quản https://news.medxy.ai/supraglottic-botulinum-toxin-injection-improves-symptoms-of-laryngeal-sensory-dysfunction/Medxy AIen2026-09-28T05:55:11-07:00Supraglottic Botulinum Toxin Injection Improves Symptoms of Laryngeal Sensory Dysfunction https://news.medxy.ai/zh/risk-benefit-balance-3/Medxy AIzh2026-09-28T05:54:37-07:00风险与获益如何平衡：双侧输卵管卵巢切除术时机对 BRCA1/2 突变携带者卵巢癌风险的影响 https://news.medxy.ai/ja/brca1-2-ovarian-cancer-risk/Medxy AIja2026-09-28T05:54:21-07:00BRCA1/2変異保有者における卵巣癌リスク：両側卵管卵巣摘出術の実施時期はどう影響するか https://news.medxy.ai/vi/ovary-tube-removal-risk/Medxy AIvi2026-09-28T05:54:02-07:00Cắt bỏ hai bên vòi trứng và buồng trứng: thời điểm phẫu thuật ảnh hưởng thế nào đến nguy cơ ung thư buồng trứng ở người mang đột biến BRCA1/BRCA2? https://news.medxy.ai/balancing-risks-the-impact-of-bilateral-salpingo-oophorectomy-timing-on-ovarian-cancer-risk-in-brca1-and-brca2-mutation-carriers/Medxy AIen2026-09-28T05:53:45-07:00Balancing Risks: The Impact of Bilateral Salpingo-Oophorectomy Timing on Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers https://news.medxy.ai/zh/tia-dementia-risk/Medxy AIzh2026-09-28T05:53:11-07:00TIA后的长期痴呆风险：一项人群研究揭示持续性的认知威胁 https://news.medxy.ai/ja/tia-dementia-risk-2/Medxy AIja2026-09-28T05:52:52-07:00TIA後の認知症リスクは長期に持続するのか：人口ベース研究が示した持続的な認知的脅威 https://news.medxy.ai/vi/long-term-dementia-risk-after-tia/Medxy AIvi2026-09-28T05:52:33-07:00Nguy cơ sa sút trí tuệ dài hạn sau TIA: Nghiên cứu dựa trên quần thể cho thấy mối đe dọa nhận thức kéo dài https://news.medxy.ai/long-term-dementia-risk-after-tia-a-population-based-study-reveals-sustained-cognitive-threat/Medxy AIen2026-09-28T05:52:13-07:00Long-Term Dementia Risk After TIA: A Population-Based Study Reveals Sustained Cognitive Threat https://news.medxy.ai/vi/semaglutide-heart-benefits/Medxy AIvi2026-09-28T05:50:52-07:00Semaglutide và lợi ích tim mạch: Giải mã phân tích trung gian từ thử nghiệm SELECT https://news.medxy.ai/unraveling-the-cardiovascular-benefits-of-semaglutide-insights-from-the-select-trial-mediation-analysis/Medxy AIen2026-09-28T05:50:34-07:00Unraveling the Cardiovascular Benefits of Semaglutide: Insights from the SELECT Trial Mediation Analysis https://news.medxy.ai/zh/78742-2/Medxy AIzh2026-09-28T05:35:30-07:00EYS相关视网膜变性：遗传多样性、临床表现及疾病进展 https://news.medxy.ai/ja/eys-retinal-degeneration-korea/Medxy AIja2026-09-28T05:35:12-07:00韓国におけるEYS関連網膜変性：遺伝的多様性、臨床像、疾患進行の新知見 https://news.medxy.ai/vi/eys-retinopathy-korea/Medxy AIvi2026-09-28T05:34:50-07:00Thoái hóa võng mạc liên quan đến EYS ở Hàn Quốc: biến thiên di truyền, đặc điểm lâm sàng và tiến triển bệnh https://news.medxy.ai/eys-associated-retinal-degeneration-in-south-korea-insights-into-genetic-variability-clinical-features-and-disease-progression/Medxy AIen2026-09-28T05:34:31-07:00EYS-Associated Retinal Degeneration in South Korea: Insights into Genetic Variability, Clinical Features, and Disease Progression https://news.medxy.ai/zh/parathyroid-identification/Medxy AIzh2026-09-28T05:33:54-07:00甲状腺切除术中甲状旁腺肉眼识别的临床价值：基于决策曲线分析的研究洞见 https://news.medxy.ai/ja/78736-2/Medxy AIja2026-09-28T05:33:35-07:00甲状腺切除術中における副甲状腺の肉眼的同定 https://news.medxy.ai/vi/parathyroid-identification-2/Medxy AIvi2026-09-28T05:33:15-07:00Đánh giá nhận diện tuyến cận giáp bằng mắt thường trong phẫu thuật cắt tuyến giáp: góc nhìn từ phân tích đường cong quyết định https://news.medxy.ai/evaluating-visual-parathyroid-identification-during-thyroidectomy-insights-from-decision-curve-analysis/Medxy AIen2026-09-28T05:32:56-07:00Evaluating Visual Parathyroid Identification During Thyroidectomy: Insights from Decision Curve Analysis https://news.medxy.ai/zh/parathyroidectomy-bisphosphonates-bone-density/Medxy AIzh2026-09-28T05:32:18-07:00甲状旁腺切除术与双膦酸盐治疗对骨密度影响的评估：来自多机构研究的启示 https://news.medxy.ai/ja/parathyroid-surgery-bisphosphonate/Medxy AIja2026-09-28T05:31:58-07:00副甲状腺摘出術とビスホスホネート療法は骨密度をどこまで改善するか：多施設研究からの知見 https://news.medxy.ai/vi/parathyroid-bisphosphonates-bone-density/Medxy AIvi2026-09-28T05:31:37-07:00Cắt tuyến cận giáp và bisphosphonates ảnh hưởng thế nào đến mật độ xương? Kết quả từ một nghiên cứu đa cơ sở https://news.medxy.ai/evaluating-the-impact-of-parathyroidectomy-and-bisphosphonate-therapy-on-bone-mineral-density-insights-from-a-multi-institutional-study/Medxy AIen2026-09-28T05:31:17-07:00Evaluating the Impact of Parathyroidectomy and Bisphosphonate Therapy on Bone Mineral Density: Insights from a Multi-Institutional Study https://news.medxy.ai/zh/tubo-ovarian-abscess/Medxy AIzh2026-09-28T05:30:39-07:00输卵管卵巢脓肿治疗新证据：经阴道引流与腹腔镜的多中心随机试验对比 https://news.medxy.ai/ja/tubo-ovarian-abscess-2/Medxy AIja2026-09-28T05:30:21-07:00卵管卵巣膿瘍に対する経腟ドレナージと腹腔鏡手術の比較：多施設ランダム化試験からの知見 https://news.medxy.ai/vi/vaginal-drainage-vs-laparoscopy/Medxy AIvi2026-09-28T05:30:03-07:00Dẫn lưu qua đường âm đạo hay nội soi ổ bụng trong áp-xe vòi trứng-buồng trứng? Kết quả từ một thử nghiệm ngẫu nhiên đa trung tâm https://news.medxy.ai/assessing-transvaginal-drainage-versus-laparoscopy-for-tubo-ovarian-abscess-insights-from-a-multicenter-randomized-trial/Medxy AIen2026-09-28T05:29:46-07:00Assessing Transvaginal Drainage Versus Laparoscopy for Tubo-Ovarian Abscess: Insights from a Multicenter Randomized Trial https://news.medxy.ai/zh/advanced-ovarian-cancer-trial/Medxy AIzh2026-09-28T05:29:11-07:00晚期上皮性卵巢癌中卡铂、紫杉醇与帕博利珠单抗联合HIPEC及奥拉帕利维持治疗的创新性Ⅱ期试验 https://news.medxy.ai/ja/ovarian-cancer-trial/Medxy AIja2026-09-28T05:28:52-07:00進行上皮性卵巣癌に対する carboplatin/paclitaxel と pembrolizumab、HIPEC および olaparib 維持療法を組み合わせた革新的第II相試験 https://news.medxy.ai/vi/advanced-phase-ii-carboplatin-paclitaxel-pembrolizumab-ovarian-cancer/Medxy AIvi2026-09-28T05:28:33-07:00Thử nghiệm pha II tiên tiến về carboplatin, paclitaxel và pembrolizumab kết hợp HIPEC cùng duy trì olaparib trong ung thư biểu mô buồng trứng tiến triển https://news.medxy.ai/innovative-phase-ii-trial-of-carboplatin-paclitaxel-and-pembrolizumab-with-hipec-and-olaparib-maintenance-in-advanced-epithelial-ovarian-cancer/Medxy AIen2026-09-28T05:28:14-07:00Innovative Phase II Trial of Carboplatin, Paclitaxel, and Pembrolizumab with HIPEC and Olaparib Maintenance in Advanced Epithelial Ovarian Cancer https://news.medxy.ai/zh/predicting-first-nations-births/Medxy AIzh2026-09-28T05:27:37-07:00预测 First Nations 妇女足月分娩：来自昆士兰队列研究的启示 https://news.medxy.ai/ja/first-nations-delivery/Medxy AIja2026-09-28T05:27:21-07:00First Nations女性の正期産を予測する：クイーンズランド・コホート研究からの知見 https://news.medxy.ai/vi/full-term-birth-forecast/Medxy AIvi2026-09-28T05:27:02-07:00Dự báo sinh đủ tháng ở phụ nữ First Nations: Phát hiện từ một nghiên cứu đoàn hệ tại Queensland https://news.medxy.ai/predicting-term-birth-among-first-nations-women-insights-from-a-queensland-cohort-study/Medxy AIen2026-09-28T05:26:45-07:00Predicting Term Birth Among First Nations Women: Insights from a Queensland Cohort Study https://news.medxy.ai/zh/78712-2/Medxy AIzh2026-09-28T05:26:10-07:00丁酰胆碱酯酶：肝纤维化潜在能靶点 https://news.medxy.ai/ja/78711-2/Medxy AIja2026-09-28T05:25:52-07:00肝線維化におけるブチリルコリンエステラーゼの役割：肝疾患における新たなコリン作動性標的 https://news.medxy.ai/vi/butyrylcholinesterase-liver-fibrosis/Medxy AIvi2026-09-28T05:25:33-07:00Vai trò của Butyrylcholinesterase trong xơ hóa gan: một mục tiêu cholinergic mới trong bệnh gan https://news.medxy.ai/unveiling-the-role-of-butyrylcholinesterase-in-hepatic-fibrosis-a-novel-cholinergic-target-in-liver-disease/Medxy AIen2026-09-28T05:25:12-07:00Unveiling the Role of Butyrylcholinesterase in Hepatic Fibrosis: A Novel Cholinergic Target in Liver Disease https://news.medxy.ai/zh/young-adult-stroke-rise/Medxy AIzh2026-09-28T05:24:36-07:00年轻成人卒中发病上升：来自人群研究的危险因素演变与死亡趋势 https://news.medxy.ai/ja/stroke-increase-young-adults/Medxy AIja2026-09-28T05:24:20-07:00若年成人で脳卒中が増加：人口ベース研究が示す危険因子の変化と死亡率の推移 https://news.medxy.ai/vi/stroke-increase-young/Medxy AIvi2026-09-28T05:23:58-07:00Đột quỵ gia tăng ở người trẻ: thay đổi hồ sơ nguy cơ và xu hướng tử vong từ một nghiên cứu dựa trên quần thể https://news.medxy.ai/rising-stroke-incidence-in-young-adults-evolving-risk-profiles-and-mortality-trends-from-a-population-based-study/Medxy AIen2026-09-28T05:23:37-07:00Rising Stroke Incidence in Young Adults: Evolving Risk Profiles and Mortality Trends from a Population-Based Study https://news.medxy.ai/zh/multidimensional-decline/Medxy AIzh2026-09-28T05:23:03-07:00多维功能衰退早于心血管事件：ASPREE 研究新启示 https://news.medxy.ai/ja/functional-decline-cardiovascular-events/Medxy AIja2026-09-28T05:22:45-07:00機能低下は心血管イベントに先行する：ASPREE研究が示す新知見 https://news.medxy.ai/vi/multidimensional-function-decline/Medxy AIvi2026-09-28T05:22:26-07:00Suy giảm chức năng đa chiều báo trước biến cố tim mạch: Góc nhìn từ nghiên cứu ASPREE https://news.medxy.ai/multidimensional-functional-decline-precedes-cardiovascular-events-insights-from-the-aspree-study/Medxy AIen2026-09-28T05:22:08-07:00Multidimensional Functional Decline Precedes Cardiovascular Events: Insights from the ASPREE Study https://news.medxy.ai/zh/af-density-stroke-risk/Medxy AIzh2026-09-28T05:21:32-07:00心房颤动密度：一种提升缺血性卒中风险预测的新型生物标志物 https://news.medxy.ai/ja/afib-density-stroke-risk/Medxy AIja2026-09-28T05:21:12-07:00心房細動密度：虚血性脳卒中リスク予測を高める新たなバイオマーカー https://news.medxy.ai/vi/afib-density-biomarker/Medxy AIvi2026-09-28T05:20:49-07:00Mật độ rung nhĩ: biomarker mới giúp dự báo chính xác hơn nguy cơ đột quỵ thiếu máu cục bộ https://news.medxy.ai/atrial-fibrillation-density-a-novel-biomarker-enhancing-ischaemic-stroke-risk-prediction/Medxy AIen2026-09-28T05:20:29-07:00Atrial Fibrillation Density: A Novel Biomarker Enhancing Ischaemic Stroke Risk Prediction https://news.medxy.ai/zh/venous-integrity/Medxy AIzh2026-09-28T02:09:59-07:00静脉完整性：预测乳头保留乳腺切除术后乳头-乳晕复合体坏死的关键指标 https://news.medxy.ai/ja/venous-integrity-nac-necrosis/Medxy AIja2026-09-28T02:09:35-07:00乳頭温存乳房切除術後NAC壊死の鍵となる予測因子としての静脈の完全性 https://news.medxy.ai/vi/vein-integrity-predictor/Medxy AIvi2026-09-28T02:09:13-07:00Tính toàn vẹn tĩnh mạch: yếu tố dự báo then chốt của hoại tử phức hợp quầng-vú sau phẫu thuật cắt tuyến vú bảo tồn núm vú https://news.medxy.ai/venous-integrity-as-a-key-predictor-of-nipple-areolar-complex-necrosis-following-nipple-sparing-mastectomy/Medxy AIen2026-09-28T02:08:53-07:00Venous Integrity as a Key Predictor of Nipple-Areolar Complex Necrosis Following Nipple-Sparing Mastectomy